[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350447-105":59,"doc-detail-350447-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","exploiting-vitamin-c-as-a-prooxidant-to-activate-ros-responsive-prodrugs-for-potent-and-selective-tumor-killing-redox-biology-95-2026-104229","Exploiting vitamin C as a prooxidant to activate ROS-responsive prodrugs for potent and selective tumor killing - Redox Biology 95 (2026) 104229","","Developing targeted cancer therapy with minimal side effects remains a significant challenge. Oxidative stress–based cancer therapies have gained traction, yet limited tumor selectivity and therapeutic durability often restrict clinical impact. This study reports a strategy combining ROS-responsive prodrugs with prooxidants to amplify oxidative stress in tumors. In vitro and in vivo results demonstrate synergistic, selective tumor killing, including complete tumor regression without recurrence, outperforming single agents.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/exploiting-vitamin-c-as-a-prooxidant-to-activate-ros-responsive-prodrugs-for-potent-and-selective-tumor-killing-redox-biology-95-2026-104229/350447/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/exploiting-vitamin-c-as-a-prooxidant-to-activate-ros-responsive-prodrugs-for-potent-and-selective-tumor-killing-redox-biology-95-2026-104229/350447.png","ImageObject",300,407,{"name":92,"@type":93},"Grenda","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the paper address in oxidative stress-based cancer therapy?","Question",{"text":112,"@type":113},"Limited tumor selectivity and therapeutic durability often hinder clinical translation. Single-agent pro-oxidants and ROS-activated prodrugs face challenges such as dose-limiting toxicity and insufficient activation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the reported strategy combining in this work?",{"text":117,"@type":113},"The study combines ROS-responsive prodrugs with prooxidants, using pro-oxidants such as ascorbate (vitamin C) to amplify oxidative stress within tumors.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes were observed regarding tumor killing and recurrence?",{"text":121,"@type":113},"Both in vitro and in vivo studies show strong anticancer synergism and selectivity. The combination therapy achieved complete tumor regression without recurrence and outperformed single-agent treatments, including against hard-to-treat triple-negative breast cancers.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350447,1790197450,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},7971474921005,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Redox Biology 95 (2026) 104229  \nContents lists available at ScienceDirect  \nRedox Biology  \njournal [homepage:](homepage: www.elsevier.com/locate/redox)[ www.elsevier.com/locate/redox](homepage: www.elsevier.com/locate/redox)  \n| Exploiting vitamin C as a prooxidant to activate ROS-responsive prodrugs for potent and selective tumor killing\u003Cbr>Taufeeque Alia,1, Thilini Nimasha Fernando Ponnamperumage a,1, Cody Joshua Miller a, Daniel Lia, Wasiu Olaniyi Awoyera a, Alexis Kimberly Peterson a, Hanlun Gao a, Jatin Pandey a, Julia Anna Rose Jakusza, Heli Fana, Gilbert Edward Koelscha, Leggy A. Arnold a,\u003Cbr>Julie M. Jornsb, Yee Chung Chengc, Avik Roy d, Gang Zhou e, Xiaohua Penga,* \u003Cbr>a Department of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, 2000 E. Kenwood Boulevard, Milwaukee, WI, 53211, USA\u003Cbr>b Department of Pathology, Medical College Wisconsin, Milwaukee, WI, USA\u003Cbr>c Department of Hematology and Oncology and Department of Medicine, Medical College Wisconsin, Milwaukee, WI, USA d Research and Development Laboratory, Simmaron Research Institute, Milwaukee, WI, USA\u003Cbr>e Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA, USA |  |  |\n| --- | --- | --- |\n| A R T I C L E I N F O |  | A B S T R A C T |\n| Keywords:\u003Cbr>Combination therapy Synergistic anticancer effects ROS-Responsive prodrugs Triple negative breast cancer ROS-Generating agents Vitamin C\u003Cbr>Complete tumor regression |  | Developing targeted cancer therapy with minimal side effects remains a significant challenge. Oxidative stressbased cancer therapies have gained traction in recent years. However, challenges such as limited tumor selectivity and therapeutic durability often hinder their clinical application. Here, we report a novel strategy of combining ROS-responsive prodrugs with prooxidants to achieve potent, durable, and selective tumor killing effects. This approach leverages pro-oxidants (i.e. ascorbate) to amplify oxidative stress within tumors, sensitizing cancer cells to ROS-responsive prodrugs. Both in vitro and in vivo studies confirm the anticancer synergism and selectivity of this combination therapy, which achieved complete tumor regression without recurrence, significantly outperforming single-agent treatments. This combination therapy is effective against hard-to-treat cancers like triple-negative breast cancers. Our findings highlight the potential of targeting tumor redox mechanisms through a combination of ROS-responsive prodrugs and pro-oxidants, offering a promising avenue for repurposing these agents in cancer therapy. |\n\n1. Introduction  \nCancer cells exhibit elevated oxidative stress due to oncogene activation, tumor suppressor gene inactivation, increased metabolism, and diminished antioxidant activities [1–4]. Consequently, cancer cells tend to have higher basal level of reactive oxygen species (ROS) than normal cells. This feature has been exploited to develop therapeutic strategies that selectively target cancer cells while sparing normal tissues. One such strategy, known as oxidative stress-based cancer therapy, involves the use of pro-oxidants to drive ROS production and accumulation to an excessive level in cancer cells, resulting in irreversible damage to DNA, proteins and lipids that lead to eventual cell death. Numerous pro-oxidants have been identified for their ability to induce oxidative stress in cancer cells, showing promising results in certain cases [2–11].  \nHowever, the application of oxidative stress-inducing pro-oxidants for cancer treatment faces many challenges, including limited tumor-selectivity, dose-limiting toxicity, inefficient drug delivery, acquired resistance, etc.  \nThe feature that cancer cells have elevated levels of ROS compared to normal cells has also been employed to develop a class of prodrugs that only become cytotoxic in the presence of ROS such as hydrogen peroxide (H2O2) [12–23]. We have previously devel","cbCaid1zOfAnUog7","https://ap.wps.com/l/cbCaid1zOfAnUog7","pdf",8144387,16,"English","# Introduction\n## Oxidative stress-based cancer therapy and pro-oxidants\n## ROS-activated prodrugs and limitations of single-agent use\n## Rationale for combining ROS-activated prodrugs with pro-oxidants","[{\"question\":\"What problem does the paper address in oxidative stress-based cancer therapy?\",\"answer\":\"Limited tumor selectivity and therapeutic durability often hinder clinical translation. Single-agent pro-oxidants and ROS-activated prodrugs face challenges such as dose-limiting toxicity and insufficient activation.\"},{\"question\":\"What is the reported strategy combining in this work?\",\"answer\":\"The study combines ROS-responsive prodrugs with prooxidants, using pro-oxidants such as ascorbate (vitamin C) to amplify oxidative stress within tumors.\"},{\"question\":\"What outcomes were observed regarding tumor killing and recurrence?\",\"answer\":\"Both in vitro and in vivo studies show strong anticancer synergism and selectivity. The combination therapy achieved complete tumor regression without recurrence and outperformed single-agent treatments, including against hard-to-treat triple-negative breast cancers.\"}]","Exploiting vitamin C as a prooxidant to activate ROS-responsive prodrugs for potent and selective tumor killing - Redox Biology 95 (2026) 104229 | PDF",1790089087,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/533a05b63de409d504d2c6c68d59a1a2.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aaaffa59aa472c1572f4e3c1bb0b36da.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/485c4cbec0a0bdc8842555aa6d1f8f25.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/356aab1202c0824a0c31170bdf012d79.webp",980,1306]